MY MENU

여름정기학술대회

2022여름초록

제목

Evaluation of the Clinical Performance of MRSA Screening Software based on MALDI-TOF MS

작성자
박종민

발표자 및 발표 내용

소속
한림대학교
발표구분
포스터발표
4. Medical / Pharmaceutical Science
Brief Oral Presentation 발표신청
신청자에 한함
Keyword
MRSA screening
Antibiotic susceptibility test
MALDI-TOF MS

주저자

이름
박종민
소속
한림대학교
국가
대한민국

공동저자

공동저자
이름
김경남
소속
연세대학교
국가
대한민국
이름
박정수
소속
서울대학교
국가
대한민국
이름
김재석
소속
한림대학교
국가
대한민국
이름
용동은
소속
연세대학교
국가
대한민국
이름
소속
국가
이름
소속
국가
이름
소속
국가
이름
소속
국가
이름
소속
국가
이름
소속
국가

접수자

이름
박종민
소속
한림대학교
Methicillin-resistant Staphylococcus aureus (MRSA) is a major cause of healthcare-associated infections such as bacteremia, pneumonia, and surgical wound infection, and it is challenging to deal with as it has resistance against many other antibiotics. Rapid detection of MRSA is essential to prevent such deadly infections, and prompt treatment of antimicrobials against MRSA improved treatment outcomes. However, traditional MRSA screening/confirmatory tests based on molecular diagnostics involve PCR, sequencing, and DNA chips plus bacterial culture with antimicrobial susceptibility tests, which are time-consuming, labor-intensive, and costly. The primary objective of this study was to evaluate the clinical performance of rapid MRSA screening software based on matrix-assisted laser desorption/ionization-time of flight  (MALDI-TOF) MS and machine learning techniques. AMRQuest software was developed to be able to compare MALDI-TOF mass spectra of S. aureus with a database by working on the machine learning technique and was successfully used to screen MRSA and identify the bacterial species simultaneously. The cefoxitin disk diffusion test was conducted to use the test results as the reference values. From the test, the sensitivity, specificity, percent agreements, and Cohen’s kappa value were calculated to determine the accuracy of the AMRQuest software. The SCCmecA gene was detected to compare the discrepancy between the cefoxitin disk diffusion test and the results of AMRQuest MRSA screening. Using the results from the AMRQuest Software, MRSA and MSSA were successfully distinguished statistically (p<0.0001), and the PPV and NPV were estimated to be 95% and 78%, respectively. In conclusion, the clinical performance of AMRQuest software for MRSA screening was evaluated to determine if it would be sufficient for use in laboratories.

게시물수정

게시물 수정을 위해 비밀번호를 입력해주세요.

댓글삭제게시물삭제

게시물 삭제를 위해 비밀번호를 입력해주세요.